MedTrace Logo

Hypertension Longitudinal Data Platform in Tianjin

NCT06415071 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1172280

Last updated 2024-05-17

No results posted yet for this study

Summary

Hypertension is one of the leading causes of death globally, and ranks among the top four risk factors for mortality and DALYs in China. However, large-scale population based longitudinal research data source for hypertension is lacking in China. Thus, we aimed to establish the first and most extensive hypertension database in China using healthcare data from the Tianjin city. This hypertension longitudinal data platformlinked electronic medical records (EMR) system 35 stores healthcare data of 1.17 million hypertension patients, from 43 tertiary hospitals and 39 secondary hospitals, along with a public health follow-up management system. Data on demographics, diagnosis, drug prescription, laboratory test, physical examination, and cost information were collected, the median follow-up time was 4.3 \[ interquartile range (IQR): 2.7-5.8\] years, and the median number of outpatient visits was 32 (IQR: 15-64) per patient. This database can address research needs including, drug utilization pattern analysis, policy implementation evaluation, digital medical device development, and other real world evidence studies. These researches would provide robust evidence to assist improving patient health outcomes and healthcare system decision-making.

Conditions

Interventions

OTHER

No intervention

Exposures of interest would be clearly defined according to a specific research question and identified from the database

Sponsors & Collaborators

  • Tianjin Health Care Big Data Ltd.

    collaborator UNKNOWN

  • Tianjin Health Commission

    collaborator UNKNOWN

  • West China Hospital

    lead OTHER

Principal Investigators

  • Xin Sun, Phd · West China Second University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06415071 on ClinicalTrials.gov